Table 2.
Mortality rates in patients with AECOPD, any COPD, or Respiratory failure due to COPD, respectively, stratified according to suPAR and CRP quartilesa
| AECOPD | any COPD | Respiratory failure | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Survived | Died | p-value | Survived | Died | p-value | Survived | Died | p-value | |
| 30-day mortality | 671 (93.6%) | 46 (6.4%) | 2338 (90.1%) | 235 (9.1%) | 210 (79.3%) | 55 (20.7%) | |||
| suPAR (ng/ml), median (IQR) | 3.5 (2.6–4.9) | 4.5 (3.5–5.8) | 0.0004 | 3.6 (2.7–5.1) | 5.7 (3.8–8.1) | < 0.0001 | 3.8 (2.8–5.1) | 4.1 (3.0–6.3) | 0.14 |
| CRP (mg/L), median (IQR) | 21 (5–75) | 46 (15–86) | 0.03 | 13 (4–57) | 71 (20–160) | < 0.0001 | 21.5 (6–80) | 43 (8.5–115) | 0.14 |
| suPAR quartile 1 | 176 (97.2%) | 5 (2.8%) | 594 (97.2%) | 17 (2.8%) | 58 (82.9%) | 12 (17.1%) | |||
| suPAR quartile 2 | 176 (95.6%) | 8 (4.4%) | 634 (94.6%) | 36 (5.4%) | 51 (79.7%) | 13 (20.3%) | |||
| suPAR quartile 3 | 165 (91.2%) | 16 (8.8%) | 583 (91.2%) | 56 (8.8%) | 54 (81.8%) | 12 (18.2%) | |||
| suPAR quartile 4 | 154 (90.1%) | 17 (9.9%) | 0.01b | 527 (80.7%) | 126 (19.3%) | < 0.0001b | 47 (72.3%) | 18 (27.7%) | 0.44b |
| CRP quartile 1 | 186 (96.9%) | 6 (3.1%) | 622 (96.4%) | 23 (3.6%) | 57 (80.3%) | 14 (19.7%) | |||
| CRP quartile 2 | 166 (94.3%) | 10 (5.7%) | 619 (95.5%) | 29 (4.5%) | 54 (85.7%) | 9 (14.3%) | |||
| CRP quartile 3 | 154 (90.1%) | 17 (9.9%) | 577 (89.6%) | 67 (10.4%) | 51 (77.3%) | 15 (22.7%) | |||
| CRP quartile 4 | 165 (92.7%) | 13 (7.3%) | 0.06b | 520 (81.8%) | 116 (18.2%) | < 0.0001b | 48 (73.8%) | 17 (26.2%) | 0.40b |
| 90-day mortality | 621 (86.6%) | 96 (13.4%) | 2203 (85.6) | 370 (14.4%) | 194 (73.2%) | 71 (26.8%) | |||
| suPAR (ng/ml), median (IQR) | 3.3 (2.6–4.6) | 4.7 (3.7–6.2) | < 0.0001 | 3.6 (2.7–5.0) | 5.4 (3.8–7.5) | < 0.0001 | 3.7 (2.8–5.0) | 4.2 (3.0–6.3) | 0.03 |
| CRP (mg/L), median (IQR) | 20 (5–75.5) | 41 (13–73) | 0.005 | 12 (3–54) | 61 (16–130) | < 0.0001 | 19 (6–82) | 43 (7–110) | 0.11 |
| suPAR quartile 1 | 174 (96.1%) | 7 (3.9%) | 583 (95.4%) | 28 (4.6%) | 55 (78.6%) | 15 (21.4%) | |||
| suPAR quartile 2 | 169 (91.9%) | 15 (8.1%) | 614 (91.6%) | 56 (8.4%) | 49 (76.6%) | 15 (23.4%) | |||
| suPAR quartile 3 | 149 (82.3%) | 32 (17.7%) | 540 (84.5%) | 99 (15.5%) | 49 (74.2%) | 17 (25.8%) | |||
| suPAR quartile 4 | 129 (75.4%) | 42 (24.6%) | < 0.0001b | 466 (71.4%) | 187 (28.6%) | < 0.0001b | 41 (63.1%) | 24 (36.9%) | 0.18b |
| CRP quartile 1 | 178 (92.7%) | 14 (7.3%) | 605 (93.8%) | 40 (6.2%) | 52 (73.2%) | 19 (26.8%) | |||
| CRP quartile 2 | 155 (88.1%) | 21 (11.9%) | 593 (91.5%) | 55 (8.5%) | 51 (81.0%) | 12 (19.0%) | |||
| CRP quartile 3 | 133 (77.8%) | 38 (22.2%) | 537 (83.4%) | 107 (16.6%) | 46 (69.7%) | 20 (30.3%) | |||
| CRP quartile 4 | 155 (87.1%) | 23 (12.9%) | 0.0004b | 468 (73.6%) | 168 (26.4%) | < 0.0001b | 45 (69.2%) | 20 (30.8%) | 0.41b |
aThe cut-offs for the suPAR quartiles in each population were as follows: AECOPD: Q1: ≤2.6 ng/ml, Q2: 2.7–3.5 ng/ml, Q3: 3.6–5.0 ng/ml, Q4: > 5 ng/ml. Any COPD: Q1: ≤2.7 ng/ml, Q2: 2.8–3.7 ng/ml, Q3: 3.8–5.3 ng/ml, Q4: ≥5.4 ng/ml. Respiratory failure: Q1: ≤2.8 ng/ml, Q2: 2.9–3.8 ng/ml, Q3: 3.9–5.3 ng/ml, Q4: ≥5.4 ng/ml
The cut-offs for the CRP quartiles in each population were as follows: AECOPD: Q1: < 6 mg/l, Q2: 6–23 mg/l, Q3: 24–74 mg/l, Q4:≥75 mg/l. Any COPD: Q1: < 4 mg/l, Q2: 4–14 mg/l, Q3: 15–64 mg/l, Q4: ≥65 mg/l. Respiratory failure: Q1: < 7 mg/l, Q2: 7–25 mg/l, Q3: 26–85 mg/l, Q4: ≥86 mg/l.
bChi2-tests by increasing suPAR and CRP-quartiles